Justification and Approval for Sole Source TPOXX Requirement
Awarded Limited / Sole Source Justification Posted
- Solicitation number
- JA-24-Edg-173
- Agency
- ACC Aberdeen Proving Ground Army Contracting Command, Department of Defense
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- W911SR-22-C-0051 Federal contract award
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Place of performance
- New York, New York 10065, United States
Notice details come from SAM.gov. Updated .
About this opportunity
This Limited/Sole Source Justification Notice from the Department of the Army Materiel Command Army Contracting Command Aberdeen Proving Ground requests approval for a sole source modification to an existing contract with SIGA Technologies Inc. to procure additional doses of the oral smallpox treatment TPOXX. The purpose is to replenish existing national stockpile quantities of TPOXX, which is the only FDA-approved treatment that meets requirements as alternatives carry safety risks. Market research found only SIGA has rights to manufacture and sell TPOXX. The agency plans to award an unspecified amount under contract number W911SR-22-C-0051 to an unknown vendor on February 15, 2024 to acquire additional doses of TPOXX.
Notice text
The purpose of this sole source within scope modification to Siga Technologies Inc., is to procure additional doses of TPOXX thereby replenishing existing National Stockpile quantities. TPOXX is an oral Smallpox Treatment in capsule form, approved by the United States Food and Drug Administration in 2018.
Awarded contract W911SR-22-C-0051 to unknown vendor for unknown amount on 2024-02-15.
Attachments
| File | Type | Posted |
|---|---|---|
| JA-24-Edg-173_TPOXX Mod_07Feb2024_redacted.pdf |
On GovTribe
Work this opportunity on GovTribe
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity